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and Stephen J Meltzer2*Abstract
Background: Esophageal cancer ranks eighth among frequent cancers worldwide. Our aim was to investigate
whether and at which neoplastic stage promoter hypermethylation of CAV1 is involved in human esophageal
carcinogenesis.
Methods: Using real-time quantitative methylation-specific PCR (qMSP), we examined CAV1 promoter hypermethylation
in 260 human esophageal tissue specimens. Real-time RT-PCR and qMSP were also performed on OE33 esophageal
cancer cells before and after treatment with the demethylating agent, 5-aza-2’-deoxycytidine (5-Aza-dC).
Results: CAV1 hypermethylation showed highly discriminative ROC curve profiles, clearly distinguishing esophageal
adenocarcinomas (EAC) and esophageal squamous cell carcinomas (ESCC) from normal esophagus (NE) (EAC vs. NE,
AUROC = 0.839 and p < 0.0001; ESCC vs. NE, AUROC = 0.920 and p < 0.0001). Both CAV1 methylation frequency and
normalized methylation value (NMV) were significantly higher in Barrett’s metaplasia (BE), low-grade and high-grade
dysplasia occurring in BE (D), EAC, and ESCC than in NE (all p < 0.01, respectively). Meanwhile, among 41 cases
with matched NE and EAC or ESCC, CAV1 NMVs in EAC and ESCC (mean = 0.273) were significantly higher than
in corresponding NE (mean = 0.146; p < 0.01, Student’s paired t-test). Treatment of OE33 EAC cells with 5-Aza-dC
reduced CAV1 methylation and increased CAV1 mRNA expression.
Conclusions: CAV1 promoter hypermethylation is a frequent event in human esophageal carcinomas and is
associated with early neoplastic progression in Barrett’s esophagus.
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Esophageal cancer ranks eighth among frequent cancers
worldwide, with estimated over 480,000 new cases diag-
nosed and 400,000 deaths globally in 2008 [1]. There
are two major histologic subtypes in esophageal cancer:
esophageal adenocarcinoma (EAC), which is more preva-
lent in Western countries, with a rapid recent rate of
increase in incidence; and esophageal squamous cell* Correspondence: zhejin1995@yahoo.com; smeltzer@jhmi.edu
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unless otherwise stated.carcinoma (ESCC), which occurs at high frequencies
in many developing countries, especially in Asia, and
including China [2]. Since esophageal cancer exhibits
highly aggressive behavior, with rapid progression to
death [3,4], it is essential to gain a better understanding of
the molecular events underlying these tumors In order
to make further inroads into survival, it is important to
discover novel early detection biomarkers and targets
for chemoprevention or therapy.
Caveolae, which are small (50–100 nanometer) invagi-
nations of the plasma membrane in many vertebrate cell
types, are vital subcellular structures that regulate endo-
cytosis, vesicular traffic, and signal transduction [5].
Caveolin-1 (CAV1), a cytoplasmic 22-kDa scaffold pro-
tein, is an essential component of caveolae [6]. In recent
years, several studies have reported downregulation ofThis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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ovarian, breast [7-10], prostate [11], oral squamous cell
[12] and lung cancer [13]. Prade et al. also showed that
the majority of EACs exhibit loss of CAV1 expression in
tumor vs. matched normal esophageal epithelia [14].
These results suggest that reduced CAV1 expression may
represent a general characteristic of tumors, and that
CAV1 may inhibit tumor formation. Aberrant methylation
of promoter CpG islands upstream of tumor suppressor
genes is now well-established as a major mechanism of
gene inactivation in tumorigenesis [15], including in ESCC
and EAC [16-23]. Several of these aberrantly methylated
genes appear to represent useful prognostic markers, as
they precede and predict the progression of BE to EAC.
Aberrant promoter methylation of CAV1 is associated
with inactivation of its expression in breast and colorectal
cancers [24-27]. Therefore, we hypothesized that CAV1
was inactivated via promoter hypermethylation in human
esophageal cancers, and that hypermethylation of CAV1
constituted an early event in the genesis of EAC.
Methods
Tissue samples
In the current study, 67 normal esophagi (NE), 60 Barrett’s
metaplasias without dysplasia (BE), 19 low-grade (LGD)
and 21 high-grade (HGD) dysplasias occurring in BE (D),
67 EACs, and 26 ESCCs were examined. Outcome data
were derived from a comprehensive database maintained
by the institution’s cancer registry and from patients’ med-
ical records at the University of Maryland and Baltimore
Veterans Affairs Medical Centers. All patients provided
written informed consent under a protocol approved
by the Institutional Review Boards at the University of
Maryland and Baltimore Veterans Affairs Medical Centers,
where all esophagogastroduodenoscopies were performed.
Biopsies were taken using a standardized biopsy protocol,
as previously described [17]. Research tissues were obtained
from grossly apparent Barrett’s epithelium or from mass
lesions in patients manifesting these changes at endo-
scopic examination, and histology was confirmed using
parallel aliquots obtained at endoscopy. All biopsy speci-
mens were stored in liquid nitrogen before DNA/RNA
extraction. Clinicopathologic characteristics are summa-
rized in Table 1.
Cell lines
The EAC (OE33) cell line was obtained from collaborators
at the University of Michigan (Dr. David Beer). These cells
were cultured in 47.5% RPMI 1640, 47.5% F-12 supple-
mented with 5% fetal bovine serum.
DNA and RNA extraction
Genomic DNA was extracted from biopsies and cultured
cells using a DNeasy Tissue Kit (Qiagen, Valencia, CA).Total RNA was isolated cultured cells using TRIzol
reagent (Invitrogen, Carlsbad, CA). DNAs and RNAs
were stored at −80°C before analysis.
Bisulfite treatment and real-time quantitative
methylation-specific PCR
DNA was treated with bisulfite to convert unmethylated
cytosines to uracils prior to qMSP, as described previously
[27]. Promoter methylation levels of CAV1 were determined
with the ABI 7900 Sequence Detection System (Applied
Biosystems, Foster City, CA), using primers and probes as
described previously [27]. A standard curve was generated
using serial dilutions of CpGenome Universal Methylated
DNA (CHEMICON, Temecula, CA). The normalized
methylation value (NMV) was defined as follows: NMV=
(CAV1-S/CAV1-FM)/(ACTB-S/ACTB-FM), where CAV1-S
and CAV1-FM represent the methylation levels of CAV1
in sample and universal methylated DNAs, respectively,
while ACTB-S and ACTB-FM correspond to ß-Actin in
sample and universal methylated DNAs, respectively [21].
Real-time quantitative RT-PCR
To determine CAV1 mRNA levels, one-step real-time
quantitative reverse-transcriptase polymerase chain reac-
tion (RT-PCR) was performed using a Qiagen QuantiTect
Probe RT-PCR Kit (Qiagen, Hilden, Germany) and the
ABI 7900 Sequence Detection System (Applied Biosystems,
Foster City, CA). Primers and probes were the same as pre-
viously reported [27]. ß-Actin was used for normalization of
data. A standard curve was generated using serial dilutions
of qPCR Reference Total RNA (Clontech, Mountainview,
CA). The normalized mRNA value (NRV) was calculated
according to the following formula for relative expression
of target mRNA: NRV= (TarS/TarC)/(ACTB-S/ACTB-C),
where TarS and TarC represent levels of mRNA expression
for the target gene in sample and control mRNAs,
respectively, whereas ACTB-S and ACTB-C correspond
to amplified ß-Actin levels in sample and control mRNAs,
respectively [21].
5-Aza-dC treatment of esophageal cancer cell lines
To determine whether CAV1 inactivation was due to
promoter hypermethylation in esophageal cancer, OE33
EAC cells were subjected to 5-Aza-dC (Sigma, St. Louis,
MO) treatment as previously described [21]. Briefly, 1 ×
105 cells/ml were seeded onto a 100 mm dish and grown
for 24 h. Then, 1 ul of 5 mM 5-Aza-dC per ml of cells was
added every 24 hours for 6 days. DNA and RNA were
harvested on day 4.
Data analysis and statistics
Receiver-operator characteristic (ROC) curve analysis [28]
was performed using NMVs for the 67 EAC, 26 ESCC
and 67 NE by Analyse-it software (Version 1.71, Analyse-





NMV Methylation status (cutoff 0.2)
Clinical characteristics Mean p Frequency UM M p
Barrett’s segment
Short-segment ( <3 cm ) 14 62.3 0.327 >0.05§ 71.4% 4 10 > 0.05‡
Long-segment ( > = 3 cm ) 16 62.8 0.439 81.3% 3 13
Histology
Normal esophagus 67 64.4 0.134 25.4% 50 17
Barrett’s metaplasia 60 63.7 0.374 < 0.01*/§ 81.7% 11 49 * < 0.01†
Dysplasia in Barrett’s esophagus 40 65.3 0.254 < 0.01*/§/ < 0.01$/§ 60.0% 16 24 * < 0.01†/ $ < 0.05†
Low-grade dysplasia 19 65.3 0.269 < 0.01*/§/ < 0.05$/§ 57.9% 8 11 * < 0.01†/ $ < 0.05†
High-grade dysplasia 21 65.2 0.240 < 0.01*/§/ < 0.01$/§ 61.9% 8 13 * < 0.01†/ $ > 0.05†
EAC 67 65.1 0.294 < 0.01*/§/ < 0.01$/§ 65.7% 23 44 * < 0.01†/ $ < 0.05†
Well differentiation 10 66.2 0.344 >0.05§§ 80.0% 2 8 > 0.05‡
Moderate differentiation 24 66.1 0.29 58.3% 10 14
Poor differentiation 22 65.5 0.297 63.6% 8 14
Unknown 11 61 0.252 72.7% 3 8
ESCC 26 62.5 0.326 < 0.01*/§ 80.8% 5 21 * < 0.01‡
Well differentiation 3 61.7 0.307 >0.05§§ 100.0% 0 3 > 0.05‡
Moderate differentiation 11 62.7 0.381 90.9% 1 10
Poor differentiation 5 64.2 0.256 80.0% 1 4
Unknown 7 61.1 0.299 57.1% 3 4
Stage of EAC patients
I 7 63 0.358 >0.05§§ 71.4% 2 5 > 0.05‡
II 15 65.2 0.286 73.3% 4 11
III 25 64.6 0.284 56.0% 11 14
IV 7 66.3 0.242 28.6% 5 2
Lymph node metastasis in EAC patients
Negative 25 64.9 0.314 >0.05§ 64.0% 9 16 > 0.05†
Positive 25 64.6 0.276 56.0% 11 14
Smoking status of EAC patients
Never 6 58.5 0.325 >0.05§§ 83.3% 1 5 > 0.05‡
Former 24 68.5 0.276 62.5% 9 15
Current 13 60.8 0.303 53.8% 6 7
Alcohol consumption of EAC patients
Never 16 65.3 0.285 >0.05§§ 68.8% 5 11 > 0.05‡
Former 15 63 0.302 66.7% 5 10
Current 10 65.7 0.315 60.0% 4 6
EAC: esophageal adenocarcinoma; ESCC: esophageal squamous cell carcinoma; NMV: normalized methylation value; UM, unmethylated; M, methylated;
§Student's t test; *comparisons made to normal esophagus; *comparisons made to Barrett’s metaplasia; §§Kruskal-Wallis test; †Chi-square for independence
test; ‡Fisher's exact test.
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under the ROC curve (AUROC) yielded optimal sensitiv-
ity and specificity to distinguish normal from malignant
esophageal tissues, and corresponding NMV thresholds
were calculated for CAV1. The cutoff value determinedfrom this ROC curve was applied to determine the fre-
quency of CAV1 methylation in each tissue type included
in the present study. For all other tests, Statistica (version
6.1; StatSoft, Inc., Tulsa, OK) was used. Differences with
p < 0.05 were deemed significant.
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CAV1 promoter hypermethylation in different
esophageal tissues
Promoter hypermethylation of the CAV1 gene was ana-
lyzed in 67 NE, 60 BE, 40 D (19 LGD and 21 HGD), 67
EAC and 26 ESCC samples. All assays in this study were
performed in duplicate format, and data showed reprodu-
cible and concordant results. CAV1 promoter hypermethy-
lation showed highly discriminative ROC curve profiles,
which clearly distinguished both EAC (p < 0.0001) and
ESCC (p <0.0001) from NE. AUROC of EAC vs. NE and
ESCC vs. NE were 0.839 and 0.920, respectively. ROC
curves with corresponding AUROCs for CAV1 of EAC vs.
NE and ESCC vs. NE are displayed in Figure 1.
The cutoff NMV for CAV1 (0.2) was chosen from
ROC curves to maximize sensitivity and specificity. Mean
NMV and frequency of CAV1 hypermethylation for each
tissue type are shown in Table 1. The mean NMV of
CAV1 was significantly higher in ESCC (0.326), EAC
(0.294), D (0.254), HGD (0.240), LGD (0.269) and BE
(0.374) than in NE (0.134; p < 0.01, Student’s t-test). The
frequency of CAV1 hypermethylation was increased in
BE (81.7%), D (60%), and EAC (65.7%) vs. NE (25.4%;
p < 0.01, p < 0.01 and p < 0.01, respectively; Chi-square for
independence test). CAV1 was hypermethylated in 21
(80.8%) of 26 ESCCs. There were no significant differences
between EAC and ESCC in mean CAV1 NMV (0.294 vs.
0.326; p > 0.05) or hypermethylation frequency (65.7% vs.
80.8%, p > 0.05). Among 41 cases with matched NE and
T (EAC or ESCC), CAV1 NMVs in T (mean = 0.273)
were significantly higher than in corresponding NE
(mean = 0.146; p < 0.01, Student’s paired t-test; Figure 2A
and B). Among 15 cases with corresponding NE, BE andFigure 1 Receiver-operator characteristic (ROC) curve analysis of norm
of normal esophagus (NE) vs. esophageal adenocarcinoma (EAC) (A), and N
the ROC curve (AUROC) conveys this biomarker’s accuracy in distinguishingEAC, one (No.8) was methylated only in EAC, three
(No.7, 13 and 17) were methylated only in BE, five (No.1,
6, 9, 14 and 28) were methylated in both BE and EAC,
and the remaining six were methylated in NE, BE and
EAC simultaneously (Figure 2C). In addition, both CAV1
mean NMV and hypermethylation frequency were signifi-
cantly higher in BE (0.374, 81.7%) than in D (0.254, 60%)
and EAC (0.294, 65.7%; p < 0.01 and p < 0.05, respectively;
Figure 3).
No significant associations were observed between CAV1
promoter hypermethylation and patient age, survival (data
not shown), smoking or alcohol consumption status,
BE segment length, tumor stage or lymph node metas-
tasis, histologic tumor differentiation, or histologic type
of esophageal carcinoma (Table 1).
CAV1 methylation and mRNA levels in OE33 cells after
5-Aza-dC treatment
OE33 cells were subjected to demethylation by 5-Aza-
dC treatment. On day 4 after 5-Aza-dC treatment, the
NMV of CAV1 was diminished, while CAV1 mRNA
levels were increased (Figure 4).
CAV1 has already been previously reported to have
tumor suppressor activity via. inhibiting cell prolifera-
tion and/or metastesis in several human cancers [29-32].
CAV1 down-regulation has been reported in many types
of cancer, including breast, lung, oral and esophagus
[9,10,12-14]. These results suggest that low expression
of CAV1 may represent a general characteristic or even
a requirement of transformed cells in many kinds of
carcinogenesis. Potential mechanisms underlying this
suppression of expression include posttranscriptional and
epigenetic changes, such as aberrant DNA methylationalized methylation value (NMV). ROC curve analysis of CAV1 NMVs
E vs. esophageal squamous cell carcinoma (ESCC) (B). The area under
NE from EAC and from ESCC in terms of its sensitivity and specificity.
Figure 2 Methylation status of CAV1 in matched esophageal tissue samples. A, NMVs of CAV1 in 41 patients with matched NE and esophageal
cancer (T, EAC or ESCC). B, methylation status of CAV1 in 41 cases with corresponding NE and T. C, methylation status of CAV1 in 15 cases with
corresponding NE, BE and EAC.
Figure 3 Methylation profiles of CAV1 in different esophageal tissue samples. A, The mean NMV of CAV1 was significantly higher in ESCC,
EAC, D, and BE than in NE, and in BE than in D and EAC. B. The frequency of CAV1 hypermethylation was significantly higher in BE, D, EAC and
ESCC than in NE, and in BE than in D and EAC. NE: normal esophagus; BE: Barrett’s metaplasia; D: Dysplasia in BE; EAC: esophageal adenocarcinoma;
ESCC: esophageal squamous cell carcinoma; *: Student’s t test, p < 0.01 (comparisons made to NE); $: Student’s t test, p < 0.01 (comparisons made to BE); †:
Chi-square for independence test, p < 0.01 (comparisons made to NE); ‡: Fisher’s exact test, p < 0.01 (comparisons made to NE); §: Chi-square for
independence test, p < 0.05 (comparisons made to BE).
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Figure 4 CAV1 methylation and mRNA expression in OE33 cells
after treatment with 5-aza-2’-deoxycytidine (5-Aza-dC). After
5-Aza-dC treatment, the NMV of CAV1 was diminished, while the
normalized mRNA value (NRV) of CAV1 was increased.
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gated hypermethylation of the CAV1 gene promoter in
primary human esophageal lesions of differing histological
types and grades. Our results demonstrate that CAV1
promoter hypermethylation occurs frequently in both
human EAC and ESCC (Table 1). CAV1 NMVs in T were
significantly higher than those in corresponding NE
(p < 0.01, Student’s paired t-test) in 41 cases with corre-
sponding NE and T (Figure 2). Moreover, hypermethylation
of the CAV1 promoter was significantly more frequent in
premalignant lesions, such as BE and D, as well as in EAC,
than in NE (Table 1). There was no significant association
between CAV1 promoter hypermethylation and histological
subtype of esophageal carcinoma (EAC vs. ESCC). These
results suggest that hypermethylation of CAV1 may
represent an early epigenetic event in these subjects,
that the frequency of this epigenetic event increases
during esophageal carcinogenesis, and that this event is
highly prevalent in human esophageal cancers.
Barrett’s carcinogenesis is a multistep process compris-
ing genetic and epigenetic alterations in tumor suppressor
genes, cell cycle-regulatory genes, and genes essential for
cell–cell adhesion [34,35]. Progressive accumulation of
gene alterations is postulated to underly the transition of
normal squamous epithelium to BE [36]. Many previous
studies, focused on promoter hypermethylation of candi-
date genes for esophageal carcinomas, have shown staged
growth in methylation frequency from nondysplastic
esophageal squamous cell mucosa to BE and finally to
EAC [15,37,38]. Interestingly, it has been suggested that
CAV1 acts as a tumor modulator in a tissue type- and
stage-dependent manner by binding several different
proteins involved in different signal transduction [6,39-42].Recently, we reported a preponderance of hypomethyla-
tion over hypermethylation events during the epigenomic
program of BE pre-progression by comparing global DNA
methylation profiles of two groups of BE patients, termed
‘progressors’ and ‘non-progressors’ [16]. Although the fre-
quency of CAV1 hypermethylation in this study increased
in parallel with esophageal carcinoma progression, the
mean NMV and frequency of CAV1 hypermethylation
were higher in BE than in D and EAC, and these differ-
ences were significant by Student’s t test (i.e., there was
an inverse correlation between CAV1 hypermethylation
and Barrett’s-associated esophageal neoplastic progression)
(Figure 3). Taken together, these data suggested that
the CAV1 promoter is relatively hypomethylated in
EAC and D vs. BE, implying that, at least in part, this
event represents an early part of the temporal program
of Barrett’s-associated esophageal neoplastic progression.
Two previous studies demonstrated that expression of
CAV1 was elevated in ESCC compared to corresponding
normal tissues, and its elevation was associated with
malignant progression and poor survival [43,44]. These
inconsistent results may have been due to different ana-
lytic methods used, ethnic groups studied, and smaller
sample sizes in the previous studies.
In accordance with previous findings [11,45,46], we
observed that methylation of CAV1 in EAC cell lines
was associated with silenced or reduced expression of
CAV1 mRNA. In this study, reversal of methylation and
restoration of CAV1 expression were induced in OE33
cells by 5-Aza-dC treatment (Figure 4). Restoration of
CAV1 mRNA expression due to 5-Aza-dC treatment is
consistent with the interpretation that DNA hyperme-
thylation silences the CAV1 gene. Although 5-Aza-dC or
its derivatives have shown potential as therapeutic anti-
cancer drugs [47-49], relatively hypomethylation of CAV1
in EAC and D vs. BE in the current study, and together
with previous data on the re-expression of CAV1 in
advance cancerf, would make CAV1 not an ideal molecu-
lar target for anti-cancer therapy involving demethylation
in EAC patients.
Conclusions
The current study indicates that hypermethylation of the
CAV1 promoter, leading to gene silencing, is a common
event in human esophageal cancer and occurs early during
Barrett’s-associated EAC. These results provide a basis for
further research on CAV1 as a potential biomarker for the
early diagnosis, classification, stratification and prognosti-
cation of esophageal cancers.
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